Prevalence of sarcopenia in patients with solid tumors: A meta‐analysis based on 81,814 patients
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; none of the 10 sources its claims cite is checked for support yet.
Abstract
Background: The purpose of the present meta‐analysis was to analyze the prevalence of sarcopenia on staging computed tomography (CT) in patients with different malignant solid tumors and in different oncologic settings based on a large sample. Methods: MEDLINE, Cochrane, and SCOPUS literature databases were screened for prevalence of sarcopenia in oncologic patients up to December 2021. Overall, 280 studies met the inclusion criteria. The methodological quality of the involved studies was checked according to the Quality Assessment of Diagnostic Studies instrument. The meta‐analysis was undertaken by using RevMan 5.4 software. DerSimonian and Laird random‐effects models with inverse‐variance weights were used. Results: The included 280 studies comprised 81,814 patients with different tumors. The prevalence of sarcopenia over all included studies was 35.3%. A prevalence of sarcopenia >50% was identified in esophageal cancer, urothelial cancer, cholangiocarcinoma, prostate cancer, sarcomas, and thyroid cancer. In head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, renal cell cancer, and ovarian cancer, the prevalence of sarcopenia varied between 35% and 50%. In colorectal cancer, gastric cancer, hepatocellular cancer, and breast cancer, the prevalence of low skeletal muscle mass was <35%. In curative setting, the prevalence of sarcopenia was 39.6% and in palliative setting, it was 49.2% ( P < 0.001). Conclusions: Sarcopenia is a frequent condition in oncology with a prevalence of 35.3%. The prevalence of sarcopenia is higher in palliative setting vs curative setting. The prevalence of sarcopenia is also different in different tumors.
Overview
CoChat Summary
TL;DR
This meta-analysis of 280 studies and 81,814 patients found an overall prevalence of sarcopenia/low skeletal muscle mass (LSMM) on staging CT of 35.3% in solid tumors. Prevalence varied by tumor type and was higher in palliative (49.2%) than curative (39.6%) settings (P < 0.001).
Key findings
- Overall sarcopenia/LSMM prevalence was 35.3% (95% CI 34.9–35.6) across 280 studies and 81,814 patients; prevalence ranged from 28.3% in colorectal cancer to 61.0% in prostate cancer.
- Prevalence >50% was identified in prostate cancer, esophageal cancer, urothelial cancer, cholangiocarcinoma, sarcomas, and thyroid cancer; 35%–50% in head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, renal cell cancer, and ovarian cancer; <35% in colorectal cancer, gastric cancer, hepatocellular cancer, and breast cancer.
- In curative setting (51,751 patients, 63.3% of all patients), prevalence was 39.6%; in palliative setting (7,476 patients, 9.1%), prevalence was 49.2% (P < 0.001). The Results text also reports palliative prevalence as 49.68%, and the Discussion as 49.4%.
- Sarcopenia definitions were heterogeneous: 75.9% of patients (62,070) were assessed with different cutoffs ranging from 23 to 47 cm²/m² in women and 29.1 to 63.94 cm²/m² in men; Prado cutoffs were used in 12.5%, BMI-adjusted cutoffs in 7.3%, and 41/43 cm²/m² cutoffs in 4.3%.
Methods
- Systematic review and meta-analysis; MEDLINE, Cochrane, and SCOPUS were screened up to December 2021 using PRISMA, yielding 8,279 records and 280 included studies.
- Inclusion criteria were original investigations of adult patients with malignant solid tumors, LSMM diagnosed on pretreatment CT by skeletal muscle index (SMI) at lumbar level 3, reported prevalence, study origin, and tumor setting (curative or palliative); exclusions included reviews, experimental studies, case reports, non-English articles, pediatric patients, non-CT diagnosis, and non-SMI L3 measurements.
- Meta-analysis used DerSimonian and Laird random-effects models with inverse-variance weights in RevMan 5.4; methodological quality was assessed with QUADAS-2, and publication bias was examined with a funnel plot and Egger test.
Limitations
- Stated by the paper: English-language studies only; most included studies were retrospective (192/280, 68.6%); publication bias was present (Egger test P = 0.001); only studies estimating sarcopenia on CT using SMI at L3 were included, excluding studies using sentinel muscles such as psoas or pectoral muscle.
- Stated by the paper: patient numbers were small for thyroid cancer (257) and melanoma (115), only one study each was reported for endometrial cancer and uterine cervical cancer, and the text states no eligible studies were identified for sarcomas, thymic cancer, adrenal gland cancer, and mesotheliomas—although Table 2 lists 2 sarcoma studies (n = 252).
- Evident from the text: SMI cutoffs were highly heterogeneous (75.9% of patients assessed with different cutoffs; ranges 23–47 cm²/m² in women and 29.1–63.94 cm²/m² in men), and palliative-setting prevalence is reported inconsistently as 49.2%, 49.68%, and 49.4% across the abstract, Results, and Discussion.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
0 Valid · 0 Not valid · 7 Not checked · 27 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In curative setting (51,751 patients, 63.3% of all patients), the prevalence of LSMM was 39.6%.”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > Prevalence of sarcopenia
plainn = 51,751- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 4 assumptions not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, renal cell cancer, and ovarian cancer, the prevalence of sarcopenia varied between 35% and 50%.”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 4 assumptions not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Finally, for some entities like sarcomas, thymic cancer, adrenal gland cancer, and mesotheliomas no studies that met the inclusion criteria, could be identified.”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In most cases (62,070 patients, 75.9%), different cut offs were used, ranging from 23 cm 2 /m 2 to 47 cm 2 /m 2 and from 29.1 cm 2 /m 2 to 63.94 cm 2 /m 2 in female and male patients, respectively.”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > Definition of sarcopenia
plainn = 62,070- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Total 67 7476 63.3 49.2 48.1-50.4”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 4 assumptions not shown here.
8 more claims
Create a free account to see all 34 claims and every source verdict.
- It may state two separate claims as one. 8
- The quote only partly states this claim. 2
- Probably not a substantial claim. 13
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
“In fact, our analysis shows that in curative setting sarcopenia occurs in 39.4%.”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
“Total 195 51,751 62.7 39.6 39.2-40.0”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
“The present analysis shows that the prevalence ranges from 27.2% to 61.0%.”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
“Colorectal cancer 47 33,221 60.6 28 (3) 27.8-28.7”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
“In palliative setting, it is significantly higher, namely 49.4%.”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
“Total 67 7476 63.3 49.2 48.1-50.4”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > Prevalence of sarcopenia
“The highest prevalence was observed in cholangiocarcinoma (55.6), prostate cancer (51.9%), esophageal cancer (50.2%), and urothelial cancer (50.0%).”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
“Sarcoma 1 163 64.0 62.0 54.5-69.4”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > Prevalence of sarcopenia
“The highest prevalence was identified in prostate cancer (76.1%), renal cell cancer (55.0%), lung cancer (51.5%), and colorectal cancer (53.0%) (Table 4).”
§ Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients > This is the first report regarding the prevalence of sarcopenia on staging CT in oncology based on a large sample.
“Esophageal cancer 2 326 66.3 74.2 69.5-79.0”
3 more findings
Create a free account to see every finding of this check.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., & Moher, D. (2021) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.02.003 · Cited by 3,490
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
Martin, L., Birdsell, L., MacDonald, N., Reiman, T., Clandinin, M. T., McCargar, L. J., Murphy, R., Ghosh, S., Sawyer, M. B., & Baracos, V. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2722 · Cited by 2,680
Meta-DiSc: a software for meta-analysis of test accuracy data
Zamora, J., Abraira, V., Muriel, A., Khan, K., & Coomarasamy, A. (2006) · BMC Medical Research Methodology · doi:10.1186/1471-2288-6-31 · Cited by 1,883
Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
Simonsen, C., de Heer, P., Bjerre, E. D., Suetta, C., Hojman, P., Pedersen, B. K., Svendsen, L. B., & Christensen, J. F. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002679 · Cited by 375
Cited by
Sayer, A. A., Cooper, R., Arai, H., Cawthon, P. M., Ntsama Essomba, M.-J., Fielding, R. A., Grounds, M. D., Witham, M. D., & Cruz-Jentoft, A. J. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00550-w · Cited by 380
Sarcopenia and malignancies: epidemiology, clinical classification and implications
Zhang, F., Wu, H.-F., Shi, H., Yu, Z., & Zhuang, C.-L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102057 · Cited by 117
Impact of sarcopenia on the prognosis and treatment of lung cancer: an umbrella review
Lin, T.-Y., Chen, Y., Wu, W., Han, D., Tsai, I., Chang, K. C., & Özçakar, L. (2022) · Discover Oncology · doi:10.1007/s12672-022-00576-0 · Cited by 70
Jacob, L., Gyasi, R. M., Oh, H. Y., Smith, L., Kostev, K., Sánchez, G. F. L., Rahmati, M., Haro, J. M., Tully, M. A., Shin, J. I., et al. (2023) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13215 · Cited by 55
Correlation between sarcopenia and esophageal cancer: a narrative review
Li, S., Xie, K., Xiao, X., Xu, P., Tang, M., & Li, D. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03304-w · Cited by 48
Metadata
- Authors
- Surov, A., & Wienke, A.
- Affiliations
- Otto-von-Guericke-Universität Magdeburg (DE)
- Martin Luther University Halle-Wittenberg (DE)
- Corresponding author
- Surov, Alexey
- Venue
- Journal of Parenteral and Enteral Nutrition
- Publisher
- Wiley
- Published
- 2022-06-19
- Volume
- 46
- Issue
- 8
- Pages
- 1761-1768
- ISSN
- 0148-6071 (ISSN-L)
- 1941-2444
- OpenAlex
- W4281688637
- Semantic Scholar
- b005bdabf2980f275e40a0a91b785104b1b2dae0
- Cited by
- 138
- References
- 25
- Citations by year
- 2026: 40 · 2025: 38 · 2024: 36 · 2023: 21 · 2022: 3
- FWCI
- 12.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Parenteral and Enteral Nutrition (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Physiology (medical) › Body Composition Measurement Techniques
- Keywords
- sarcopenia, solid tumors, prevalence, computed tomography staging, skeletal muscle mass, cancer cachexia, palliative care, curative cancer treatment, esophageal cancer, prostate cancer, head and neck squamous cell carcinoma, lung cancer, colorectal cancer, breast cancer
- MeSH terms
- Humans, Male, Pancreatic Neoplasms, Tomography, X-Ray Computed, Prevalence, Databases, Factual, Muscle, Skeletal, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


